An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

ClinicalTrials.gov ID: NCT00420056

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00420056. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a pilot study evaluating tumor activity using Positron Emission Tomography, which is also known as a "PET scan". This study will assess the safety of using PD-0332991 in patients with mantle cell lymphoma.

Study identification

NCT ID: NCT00420056
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Pfizer; Industry
Enrollment: 17 participants

Conditions and interventions

Conditions

Lymphoma, Mantle-Cell

Interventions

PD-0332991 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2007 (Type not available)
Primary completion: Mar 2010 (Actual)
Completion: Mar 2012 (Actual)
Last update posted: Oct 28, 2015

2007 – 2012

United States locations

U.S. sites: 6
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Brigham & Women's Hospital	Boston	Massachusetts	02115	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02115	—
Memorial Sloan-Kettering Cancer Center	New York	New York	10021	—
New York Presbyterian Hospital	New York	New York	10021	—
Weill Medical College of Cornell University - New York Presbyterian Hospital	New York	New York	10021	—
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00420056, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 28, 2015 · Synced Nov 15, 2026